Skip to main content
Clinical Trials/NCT05210114
NCT05210114
Recruiting
Not Applicable

Cutaneous Hydration Assessment in Sickle Cell Disease

Enrico Novelli1 site in 1 country30 target enrollmentJanuary 21, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sickle Cell Disease
Sponsor
Enrico Novelli
Enrollment
30
Locations
1
Primary Endpoint
Dermal water content measurements before fluid resuscitation in SCD participants with VOC or VOE
Status
Recruiting
Last Updated
5 months ago

Overview

Brief Summary

This study will validate the diagnostic accuracy of a cutaneous hydration sensor. This sensor will also be evaluated for its feasibility as a point-of-care device for the assessment of hydration status and its potential to guide hydration therapy in patients with sickle cell disease (SCD).

Detailed Description

Vaso-occlusive episodes (VOE) are the leading cause of hospitalization for patients with SCD. Intravenous fluid replacement is one of the cornerstones of management of VOE in the emergency department and throughout hospitalization. However, there are no evidence-based guidelines specifying the optimal administration of maintenance fluids. Overly aggressive hydration therapy imparts the risk of hypervolemia and pulmonary edema, which may lead to acute chest syndrome and death. Thus, a reliable biomarker is needed to gauge hydration status and guide fluid replacement strategies with the goal of achieving euvolemia. The investigators propose a point-of-care test that may inform management (e.g., bolus vs. continuous infusion of maintenance intravenous fluid), and prevent over- or under-hydration. For this purpose, investigators seek to validate the diagnostic accuracy of a cutaneous hydration sensor, Delfin MoistureMeterEpiD (a non-significant risk device) and evaluate its feasibility as a point-of-care device for the assessment of hydration status and potentially guide hydration therapy in patients with SCD. Investigators will measure skin hydration in the clinic when participants are at baseline state of health. Skin hydration before and after fluid resuscitation therapy in patients with vaso-occlusive crisis (VOC) or VOE will also be assessed. Blood and urine will be collected to compare assessments of skin hydration with laboratory biomarkers of hypertonicity and red blood cell dehydration.

Registry
clinicaltrials.gov
Start Date
January 21, 2022
End Date
December 31, 2027
Last Updated
5 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

Enrico Novelli

Associate Professor and Section Chief - Classical Hematology

University of Pittsburgh

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of Sickle Cell Disease (genotypes SS, SC, Sß-thalassemia, SD, SOArab)
  • Participants must be ≥12-years old
  • Participants that provide legally effective consent to all study procedures

Exclusion Criteria

  • Participants under 12-years old
  • Participants being treated with experimental therapies in clinical trials

Outcomes

Primary Outcomes

Dermal water content measurements before fluid resuscitation in SCD participants with VOC or VOE

Time Frame: During a VOC or VOE event before IV fluid resuscitation, approximately 2 hours

Delfin MoistureMeterEpiD hydration sensor will be used to measure dermal water content in 10 participants.

Dermal water content measurements in SCD participants at baseline state of health

Time Frame: During a regularly scheduled clinic appointment, approximately 2 hours

Delfin MoistureMeterEpiD hydration sensor will be used to measure dermal water content in 20 participants at 1 time point.

Clinical dehydration assessments in SCD participants

Time Frame: At a regularly scheduled clinical appointment, approximately 2 hours

Clinical assessment of dehydration will be ascertained by administering the 10-point Clinical Dehydration Scale (CDS). CDS uses clinical characteristics (general appearance, eyes, mucous membranes, and tears), each of which are scored 0, 1, or 2 for a total score of 0 to 8, with 0 representing no dehydration; 1 to 4, some dehydration; and 5 to 8, moderate/severe dehydration. It will be administered at 1 time point in 20 participants.

Measurement of hyperadhesion as a laboratory biomarker of dehydration in SCD participants

Time Frame: At a regularly scheduled clinical appointment, approximately 2 hours

As a marker of hyperadhesion capillary transit time will be measured using capillary mimicking microfluidic channels. It will be measured at 1 timepoint in 20 participants.

Measurement of urine osmolality as a laboratory biomarker of dehydration in SCD participants

Time Frame: At a regularly scheduled clinical appointment, approximately 2 hours

Urine osmolality values \<450 milliosmol/kg is considered abnormal in adults without fluid restrictions. It will be measured at 1 timepoint in 20 participants.

Measurement of point of sickling as a cellular biomarker of dehydration before fluid resuscitation therapy in SCD participants with VOC or VOE

Time Frame: During a VOC or VOE event before fluid resuscitation therapy, approximately 2 hours

Cellular dehydration marker, the elongation index will be measured by ektacytometry. It will be measured at 1 timepoint in 10 participants.

Measurement of serum osmolality as a laboratory biomarker of dehydration before resuscitation therapy in SCD participants with VOC or VOE

Time Frame: During a VOC or VOE event before resuscitation therapy, approximately 2 hours

Serum osmolality values of \>290 milliosmol/kg is considered abnormal. It will be measured at 1 timepoint in 10 participants.

Measurement of hyperadhesion as a laboratory biomarker of dehydration before fluid resuscitation therapy in SCD participants with VOC or VOE

Time Frame: During a VOC or VOE event before fluid resuscitation therapy, approximately 2 hours

As a marker of hyperadhesion, capillary transit time will be measured using capillary mimicking microfluidic channels. It will be measured at 1 timepoint in 10 participants.

Dermal water content measurements after fluid resuscitation in SCD participants with VOC or VOE

Time Frame: During a VOC or VOE event after IV fluid resuscitation, approximately 2 hours

Delfin MoistureMeterEpiD hydration sensor will be used to measure dermal water content in 10 participants.

Measurement of serum osmolality as a laboratory biomarker of dehydration in SCD participants

Time Frame: At a regularly scheduled clinical appointment, approximately 2 hours

Serum osmolality values of \>290 milliosmol/kg is considered abnormal. It will be measured at 1 timepoint in 20 participants.

Measurement of elongation index as a cellular biomarker of dehydration in SCD participants

Time Frame: At a regularly scheduled clinical appointment, approximately 2 hours

Cellular dehydration marker, the elongation index, will be measured by ektacytometry. It will be measured at 1 timepoint in 20 participants.

Measurement of point of sickling as a biomarker of dehydration in SCD participants

Time Frame: At a regularly scheduled clinical appointment, approximately 2 hours

Point of sickling, a cellular dehydration biomarker, will be measured by ektacytometry. It will be measured at 1 timepoint in 20 participants.

Measurement of urine osmolality as laboratory biomarkers of dehydration after fluid resuscitation therapy in SCD participants with VOC or VOE

Time Frame: During a VOC or VOE event after fluid resuscitation therapy, approximately 2 hours

Urine osmolality values \<450 milliosmol/kg is considered abnormal in adults without fluid restrictions. It will be measured at 1 timepoint in 10 participants.

Measurement of serum osmolality as a laboratory biomarker of dehydration after fluid resuscitation therapy in SCD participants with VOC or VOE

Time Frame: During a VOC or VOE event after fluid resuscitation therapy, approximately 2 hours

Serum osmolality values of \>290 milliosmol/kg is considered abnormal. It will be measured at 1 timepoint in 10 participants.

Measurement of elongation index as a cellular biomarker of dehydration after fluid resuscitation therapy in SCD participants with VOC or VOE

Time Frame: During a VOC or VOE event after fluid resuscitation therapy, approximately 2 hours

Cellular dehydration marker, the elongation index will be measured by ektacytometry. It will be measured at 1 timepoint in 10 participants.

Measurement of urine osmolality as laboratory biomarkers of dehydration before fluid resuscitation therapy in SCD participants with VOC or VOE

Time Frame: During a VOC or VOE event before fluid resuscitation therapy, approximately 2 hours

Urine osmolality values \<450 milliosmol/kg is considered abnormal in adults without fluid restrictions. It will be measured at 1 timepoint in 10 participants.

Measurement of point of sickling as a cellular biomarker of dehydration after fluid resuscitation therapy in SCD participants with VOC or VOE

Time Frame: During a VOC or VOE event after fluid resuscitation therapy, approximately 2 hours

Cellular dehydration marker, the elongation index will be measured by ektacytometry. It will be measured at 1 timepoint in 10 participants.

Measurement of hyperadhesion as a laboratory biomarker of dehydration after fluid resuscitation therapy in SCD participants with VOC or VOE

Time Frame: During a VOC or VOE event after fluid resuscitation therapy, approximately 2 hours

As a marker of hyperadhesion, capillary transit time will be measured using capillary mimicking microfluidic channels. It will be measured at 1 timepoint in 10 participants.

Measurement of elongation index as a cellular biomarker of dehydration before resuscitation therapy in SCD participants with VOC or VOE

Time Frame: During a VOC or VOE event before fluid resuscitation, approximately 2 hours

Cellular dehydration marker, the elongation index, will be measured by ektacytometry. It will be measured at 1 timepoint in 10 participants.

Study Sites (1)

Loading locations...

Similar Trials